SCHEMBL7005405

SCHEMBL7005405

O=Cc1cc(F)ccc1/C=C/c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFE2L2 Q16236 13/20 0.53
HTR2A P28223 1/20 0.51
HTR2C P28335 1/20 0.51
KCNH2 Q12809 1/20 0.51
TUBB4A P04350 1/20 0.49
TUBB P07437 1/20 0.49
TUBA3C P0DPH7 1/20 0.49
TUBA1B P68363 1/20 0.49
TUBA4A P68366 1/20 0.49
TUBB4B P68371 1/20 0.49
TUBB3 Q13509 1/20 0.49
TUBB2A Q13885 1/20 0.49
TUBB8 Q3ZCM7 1/20 0.49
TUBA3E Q6PEY2 1/20 0.49
TUBA1A Q71U36 1/20 0.49
TUBA1C Q9BQE3 1/20 0.49
TUBB6 Q9BUF5 1/20 0.49
TUBB2B Q9BVA1 1/20 0.49
TUBB1 Q9H4B7 1/20 0.49
MAOB P27338 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28524009 0.80 NFE2L2 (0.55) NFE2L2HTR2AHTR2CKCNH2TUBB4A
SCHEMBL1755404 0.79 NFE2L2 (0.78) NFE2L2HTR2AHTR2CKCNH2
SCHEMBL723353 0.79 NFE2L2 (0.78) NFE2L2HTR2AHTR2CKCNH2
SCHEMBL723352 0.79 NFE2L2 (0.78) NFE2L2HTR2AHTR2CKCNH2
SCHEMBL2290866 0.79 NFE2L2 (0.70) NFE2L2TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL2290859 0.79 NFE2L2 (0.70) NFE2L2TUBB4ATUBBTUBA3CTUBA1B
Formaldehyde SCHEMBL28876831 0.79 NFE2L2 (0.70) NFE2L2HTR2AHTR2CKCNH2TUBB4A
SCHEMBL24385991 0.78 LMNA (0.62) NFE2L2MAOB
SCHEMBL30958792 0.78 LMNA (0.62) NFE2L2MAOB
SCHEMBL192399 0.78 LMNA (0.62) NFE2L2MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8183271-B2 Tetrazole derivatives and their use for the treatment of cardiovascular diseases BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-05-22 US disclosed
US-7998988-B2 Biphenyl compounds useful in the treatment or prevention of cardiovascular disorders BAYER SCHERING PHARMA AKTIENGELLSCHAFT (DE) 2011-08-16 US disclosed
US-20090227640-A1 Heterocyclic compounds with carboxyl isostere groups and their use for the treatment of cardiovascular diseases BAYER HEALTHCARE AG (DE) 2009-09-10 US disclosed
US-20090215843-A1 Tetrazole Derivatives and Their Use for the Treatment of Cardiovascular Diseases BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2009-08-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227640-A1 Heterocyclic compounds with carboxyl isostere groups and their use for the treatment of cardiovascular diseases TNNI3, PC, TNNT2 NFE2L2 152/4885HTR2A 2615/4885HTR2C 1831/4885
US-20090215843-A1 Tetrazole Derivatives and Their Use for the Treatment of Cardiovascular Diseases TNNI3, TNNT2, FABP3 NFE2L2 652/4885HTR2A 4432/4885HTR2C 4151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.